Catharina Busch, MD

VANCOUVER, British Columbia — At the Association for Research in Vision and Ophthalmology meeting, Catharina Busch, MD, discusses results of the OBTAIN study, a retrospective study comparing 12-month outcomes of untreated and treated diabetic macular edema with very good baseline visual acuity in a real world setting. The majority of patients with good visual acuity maintained vision at 12 months regardless of whether or not DME treatment was conducted.

VIENNA — At the Euretina meeting, Catharina Busch, MD, discusses the results of a study showing patients with diabetic macular edema who do not respond to an anti-VEGF loading dose may benefit from dexamethasone steroid treatment with the Ozurdex (Allergan) implant.

HONOLULU — Repeated dexamethasone inserts are a safe option for diabetic macular edema, especially for treatment-naive eyes, according to an International Retina Group study presented by Catharina Busch, MD, at the Association for Research in Vision and Ophthalmology meeting here.